<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156353">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01849692</url>
  </required_header>
  <id_info>
    <org_study_id>C-13-001</org_study_id>
    <nct_id>NCT01849692</nct_id>
  </id_info>
  <brief_title>ESBA1008 Microvolume Study</brief_title>
  <official_title>A Prospective, Two-Staged, Single-Masked Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects With Exudative Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate a treatment effect of ESBA1008 applied as a
      microvolume injection or infusion on retinal function and morphology in subjects with
      exudative age-related macular degeneration (AMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 4-cohort study will be conducted in 2 stages. In Stage 1, subjects will be randomized
      to receive 2 ESBA1008 injections (Cohort 1), 1 ESBA1008 infusion and 1 injection (Cohort 2),
      or 2 LUCENTIS injections (Cohort 1 and 2).  Stage 2 will be conducted similarly with a
      different dosing level for ESBA1008 (Cohort 3 and 4). After the Day 28 visit (all cohorts),
      subjects will return for follow up visits at Day 42 and Day 56.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Response based upon central subfield thickness (CSFT) and best-corrected visual acuity (BCVA) outcomes at Day 14 and Day 28</measure>
    <time_frame>Baseline, up to Day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>A subject will be considered a responder if at least 3 out of the following 4 criteria are fulfilled in comparison to baseline:
Protocol-specified letter gain in BCVA at Day 14
Protocol-specified letter gain in BCVA at Day 28
Protocol-specified micron loss in CSFT at Day 14
Protocol-specified micron loss in CSFT at Day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>Baseline, up to Day 56</time_frame>
    <safety_issue>No</safety_issue>
    <description>As measured by Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Central Subfield Thickness (CSFT)</measure>
    <time_frame>Baseline, up to Day 56</time_frame>
    <safety_issue>No</safety_issue>
    <description>As measured by Spectral-Domain Optical Coherence Tomography (SD-OCT)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Exudative Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESBA1008 solution Day 0 (Dose A) and Day 28 (Dose B), or Ranibizumab Day 0 and Day 28, based on randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESBA1008 solution Day 0 (Dose D) and Day 28 (Dose B), or Ranibizumab Day 0 and Day 28, based on randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESBA1008 solution Day 0 (Dose C) and Day 28 (Dose B), or Ranibizumab Day 0 and Day 28, based on randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESBA1008 solution Day 0 (Dose E) and Day 28 (Dose B), or Ranibizumab Day 0 and Day 28, based on randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ESBA1008 solution</intervention_name>
    <description>Dose A, B, C: single intravitreal injection; Dose D, E: infusion</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>0.5 mg/50 Î¼L, single intravitreal injection</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>LUCENTIS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign informed consent document;

          -  Able to make the required study visits and follow instructions;

          -  Age-related macular degeneration in the study eye;

          -  Visual acuity within protocol-specified range;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Both eyes: Any active infection or inflammation;

          -  Study eye: Any treatment for exudative age-related macular degeneration (AMD) other
             than vitamin supplements;

          -  Study eye: Any current or history of macular or retinal disease;

          -  Study eye: Any concurrent intraocular condition such as cataract or diabetic
             retinopathy that, in the opinion of the Investigator, could either require medical or
             surgical intervention during the course of the study to prevent or treat visual loss;

          -  Study eye: Other ocular conditions or diseases that, in the opinion of the
             Investigator, could compromise visual acuity;

          -  Study Eye: Uncontrolled glaucoma;

          -  History of a medical condition that, in the opinion of the Investigator, would
             preclude scheduled study visits, completion of the study, or a safe administration of
             investigational product;

          -  Women of childbearing potential who are lactating, pregnant, planning to become
             pregnant, or not using adequate birth control methods for the duration of the study;

          -  Intraocular surgery within 3 months of baseline;

          -  Study eye: Any history or current evidence of retinal angiomatous proliferation (RAP)
             lesions based on clinical exam;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Yanni, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alcon Call Center</last_name>
    <phone>1-888-451-3937</phone>
    <email>alcon.medinfo@alcon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>May 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exudative Age-Related Macular Degeneration</keyword>
  <keyword>Wet AMD</keyword>
  <keyword>Choroidal neovascularization (CNV)</keyword>
  <keyword>Vascular endothelial growth factor (VEGF)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
